Clinical Trials /

Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer

NCT04595019

Description:

The purpose of this research is to investigate whether stereotactic body radiotherapy (SBRT), precise X-ray treatment, is best given in five treatments (also called fractions) over 10 days or in two treatments over 8 days. SBRT is an accurate way to deliver a high dose of radiotherapy to the prostate in a smaller number of doses. We have considerable experience with 5-dose SBRT and now wish to examine the feasibility and safety of delivering treatment over two, larger, doses. Previous work has shown it is theoretically possible to deliver two fraction SBRT on the MR-linac and previous studies have shown internal radiotherapy (brachytherapy) administered in two fractions to be a safe option for patients with low-risk prostate cancer. All treatment within this trial will be delivered on a new, state of the art, radiotherapy machine called an MR-linac (Magnetic Resonance Linear Accelerator). It puts together an MRI scanner with a radiotherapy treatment machine called a Linear Accelerator. The use of the MR-linac means there is no extra radiation dose given when taking images (unlike computerized tomography (CT) scans or X-ray), enabling us to adapt the radiotherapy plan each day if needed to more precisely target the prostate. The results of the study will enable us to find out if the new, shorter treatment (2 doses of radiotherapy), has a similar level of side effects as the 5 dose treatment and is suitable for further study.

Related Conditions:
  • Prostate Adenocarcinoma
Recruiting Status:

Not yet recruiting

Phase:

N/A

Trial Eligibility

Document

Title

  • Brief Title: Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer
  • Official Title: The HERMES Trial Hypofractionated Expedited Radiotherapy for Men With localisEd proState Cancer. A Phase II Randomised Trial of Ultrahypofractionated Stereotactic Body Radiotherapy in Men With Localised Prostate Cancer

Clinical Trial IDs

  • ORG STUDY ID: ICR-CTSU/2020/10070
  • SECONDARY ID: CCR5273
  • SECONDARY ID: 285291
  • NCT ID: NCT04595019

Conditions

  • Prostate Cancer

Purpose

The purpose of this research is to investigate whether stereotactic body radiotherapy (SBRT), precise X-ray treatment, is best given in five treatments (also called fractions) over 10 days or in two treatments over 8 days. SBRT is an accurate way to deliver a high dose of radiotherapy to the prostate in a smaller number of doses. We have considerable experience with 5-dose SBRT and now wish to examine the feasibility and safety of delivering treatment over two, larger, doses. Previous work has shown it is theoretically possible to deliver two fraction SBRT on the MR-linac and previous studies have shown internal radiotherapy (brachytherapy) administered in two fractions to be a safe option for patients with low-risk prostate cancer. All treatment within this trial will be delivered on a new, state of the art, radiotherapy machine called an MR-linac (Magnetic Resonance Linear Accelerator). It puts together an MRI scanner with a radiotherapy treatment machine called a Linear Accelerator. The use of the MR-linac means there is no extra radiation dose given when taking images (unlike computerized tomography (CT) scans or X-ray), enabling us to adapt the radiotherapy plan each day if needed to more precisely target the prostate. The results of the study will enable us to find out if the new, shorter treatment (2 doses of radiotherapy), has a similar level of side effects as the 5 dose treatment and is suitable for further study.

Trial Arms

NameTypeDescriptionInterventions
5 fractionActive ComparatorMRI-guided radiotherapy, 36.25 Gray (Gy) in 5 fractions (boost to 40 Gy over tumour/prostate CTV) over 10 days.
    2 fractionExperimentalMRI-guided radiotherapy, 24 Gy in 2 fractions (boost to 27 Gy over tumour/prostate CTV) over 8 days.

      Eligibility Criteria

              Inclusion Criteria:
      
                1. Men aged ≥18 years
      
                2. Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
      
                3. Gleason score 3+4 or 4+3 (Grade groups 2 or 3)
      
                4. MRI stage T3a or less
      
                5. PSA <25 ng/ml prior to starting ADT (Androgen deprivation therapy)
      
                6. Patients will be concurrently treated with androgen deprivation therapy (ADT) for at
                   least 6 months, as per standard of care. Men who need longer courses of ADT (maximum
                   12 months) will be considered on a case-by-case basis, and bicalutamide monotherapy is
                   accepted as an alternative to LHRH (luteinizing hormone-releasing hormone) analogues
                   if required.
      
                7. WHO (World Health Organisation) Performance status 0-2
      
                8. Ability of the participant understand and the willingness to sign a written informed
                   consent form.
      
                9. Ability/willingness to comply with the patient reported outcome questionnaires
                   schedule throughout the study.
      
              Exclusion Criteria:
      
                1. Contraindications to MRI (e.g. pacemaker, potentially mobile metal implant,
                   claustrophobia)
      
                2. International Prostate Symptom Score (IPSS) 13 or higher
      
                3. Post-void residual >100 mls
      
                4. Prostate volume >80cc
      
                5. Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel
                   disease) or preclude long term follow up
      
                6. Unilateral or bilateral total hip replacement, or other pelvic metalwork which causes
                   artefact on diffusion-weighted imaging
      
                7. Previous pelvic radiotherapy
      
                8. Patients needing 2-3 years of ADT due to disease parameters.
      
                9. Previous invasive malignancy within the last 2 years excluding basal or squamous cell
                   carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming
                   cystoscopic follow up now negative) or small renal masses on surveillance.
            
      Maximum Eligible Age:N/A
      Minimum Eligible Age:18 Years
      Eligible Gender:Male
      Healthy Volunteers:No

      Primary Outcome Measures

      Measure:Genitourinary (GU) toxicity
      Time Frame:12 weeks
      Safety Issue:
      Description:The proportion of patients experiencing CTCAE (Common Terminology Criteria for Adverse Events) Grade 2+ genitourinary (GU) toxicity from the start of radiotherapy up to 12 weeks post-treatment.

      Secondary Outcome Measures

      Measure:Physician-reported CTCAE Genitourinary (GU) and Gastrointestinal (GI) toxicity
      Time Frame:12 weeks
      Safety Issue:
      Description:Physician-reported CTCAE GU and GI toxicity will be reported during treatment and at 12 weeks post-treatment will be summarised according to grade and treatment received using descriptive statistics at each time point.
      Measure:Physician-reported CTCAE Genitourinary (GU) and Gastrointestinal (GI) late toxicity
      Time Frame:1, 2 and 5 years
      Safety Issue:
      Description:Late toxicity (CTCAE) at 1, 2 and 5 years post-treatment will be summarised according to grade and treatment received at each time point.
      Measure:Quality of life patient-reported outcomes
      Time Frame:12 weeks, 1, 2 and 5 years post treatment.
      Safety Issue:
      Description:Combined data from the IPSS (International Prostate Symptom Score), EPIC-26 (Expanded Prostate Index Composite-26), EQ-5D (EuroQol-5D) and IIEF-5 (International Index of Erectile Function) QOL instruments will be summarised. Domain scores from the quality of life patient-reported outcome tools will be derived using standard algorithms with missing data handled accordingly. Domain scores and individual items from the patient questionnaires will be presented graphically at each time point and summarised using descriptive statistics, separately for each treatment group. Changes from baseline will be assessed within treatment groups, and multiple regression models (e.g. ANCOVA, ordinal logistic regression or longitudinal models) will investigate patient and clinical factors that may be associated with change in patient-reported outcomes.
      Measure:PSA (Prostate Specific Antigen) control and biochemical failure/progression
      Time Frame:2 and 5 years
      Safety Issue:
      Description:Time to event.

      Details

      Phase:N/A
      Primary Purpose:Interventional
      Overall Status:Not yet recruiting
      Lead Sponsor:Institute of Cancer Research, United Kingdom

      Last Updated

      October 14, 2020